RASAL2 and nasopharyngeal carcinoma: RASAL2 is a member of RAS GTPase-activating proteins (RAS-GAPs), which can catalyze GTP into GDP and inactivate RAS.12, 13 Several preliminary studies have reported the aberrant expression of RASAL2 in different cancer types, including breast cancer, ovarian cancer, lung cancer and nasopharyngeal carcinoma.14, 15, 16, 17, 18 However, its tumor-suppressive or oncogenic roles in cancer development remain controversial,16, 18 especially, its expression and function in BCa are completely unknown.